NCT02358668View on ClinicalTrials.gov

BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 19, 2016

Conditions
Pre-Diabetes
Interventions
DRUG

BTI320

BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.

DRUG

BTI320 matching placebo

Placebo

Trial Locations (1)

Unknown

The Chinese University of Hong Kong, Shatin

All Listed Sponsors
collaborator

Sugardown Company Limited

INDUSTRY

lead

Chinese University of Hong Kong

OTHER

NCT02358668 - BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes | Biotech Hunter | Biotech Hunter